Bayer will cap R&D budget at $4.1B

With R&D expenses expected to surge 13 percent this year at Bayer, Germany's largest drug company, CEO Marijn Dekkers is telling reporters that he plans to make sure the budget item flatlines at $4.1 billion for 2011. Dekkers also noted that he was concerned "whether society will be prepared to pay an appropriate price for innovations in the future." Report